{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:42:49Z","timestamp":1793148169423,"version":"4.5.0"},"reference-count":31,"publisher":"European Respiratory Society (ERS)","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2023,9,25]]},"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Randomised controlled trials have shown that benralizumab, an anti-interleukin-5 receptor monoclonal antibody, reduces exacerbations and oral corticosteroid dose and improves asthma control and lung function in severe eosinophilic asthma. The aim of this study was to confirm results of randomised controlled trials in real life in a population of 73 patients with severe eosinophilic asthma treated with benralizumab for at least 12\u2005months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients underwent careful monitoring of asthma exacerbations, exhaled nitric oxide fraction, lung function, asthma control and quality of life questionnaire responses and sputum induction, and gave a blood sample at baseline, after 6\u2005months and then every year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found significant reductions in exacerbations (by 92%, p&lt;0.0001) and oral corticosteroid dose (by 83%, p&lt;0.001) after 6\u2005months that were maintained over time, with 78% of patients able to stop oral corticosteroid therapy. Patients improved their Asthma Control Test (ACT) score (from 11.7\u00b15.1 to 16.9\u00b15.35, p&lt;0.0001), Asthma Control Questionnaire (ACQ) score (from 2.88\u00b11.26 to 1.77\u00b11.32, p&lt;0.0001) and Asthma Quality of Life Questionnaire score (+1.04, p&lt;0.0001) at 6\u2005months and this was maintained during follow-up. Only 35% and 43% of patients reached asthma control according to an ACT score \u226520 and ACQ score &lt;1.5, respectively. We observed stable post-bronchodilation lung function over time and a significant reduction in sputum eosinophil count, with 85% of patients exhibiting sputum eosinophil counts &lt;3% after 6\u2005months (p&lt;0.01) with no effect on exhaled nitric oxide fraction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In our real-life study, we confirm the results published in randomised controlled trials showing a sharp reduction in exacerbations and oral corticosteroid therapy, an improvement in asthma control and quality of life, and a dramatic reduction in sputum eosinophil count.<\/jats:p><\/jats:sec>","DOI":"10.1183\/23120541.00383-2023","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T11:18:54Z","timestamp":1701083934000},"page":"00383-2023","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Benralizumab in severe eosinophilic asthma in real life: confirmed effectiveness and contrasted effect on sputum eosinophilia<i>versus<\/i>exhaled nitric oxide fraction \u2013 PROMISE"],"prefix":"10.1183","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2678-1373","authenticated-orcid":false,"given":"Florence","family":"Schleich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9558-5878","authenticated-orcid":false,"given":"Catherine","family":"Moermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Seidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9681-3978","authenticated-orcid":false,"given":"C\u00e9line","family":"Kempeneers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Rogister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Tombu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Pottier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1247-2334","authenticated-orcid":false,"given":"Anne-Lise","family":"Poirrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Ziant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Henket","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Paulus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Guissard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Fran\u00e7oise","family":"Donneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"key":"2024101710321938000_9.6.00383-2023.1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00201813"},{"key":"2024101710321938000_9.6.00383-2023.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.10.007"},{"key":"2024101710321938000_9.6.00383-2023.3","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"2024101710321938000_9.6.00383-2023.4","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0193-2022"},{"key":"2024101710321938000_9.6.00383-2023.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2008.10.008"},{"key":"2024101710321938000_9.6.00383-2023.6","doi-asserted-by":"crossref","first-page":"106202","DOI":"10.1016\/j.rmed.2020.106202","article-title":"Clinical and biological factors associated with irreversible airway obstruction in adult asthma","volume":"175","author":"Graff","year":"2020","journal-title":"Respir Med"},{"key":"2024101710321938000_9.6.00383-2023.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"2024101710321938000_9.6.00383-2023.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31322-8"},{"key":"2024101710321938000_9.6.00383-2023.9","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"2024101710321938000_9.6.00383-2023.10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(21)00352-0","article-title":"Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study","volume":"10","author":"Menzies-Gow","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2024101710321938000_9.6.00383-2023.11","unstructured":"Global Initiative for Asthma (GINA) . Global Strategy for Asthma Management and Prevention. 2018. Available from: http:\/\/ginasthma.org\/"},{"key":"2024101710321938000_9.6.00383-2023.12","doi-asserted-by":"publisher","DOI":"10.1136\/thx.47.2.76"},{"key":"2024101710321938000_9.6.00383-2023.13","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.1999.14d29.x"},{"key":"2024101710321938000_9.6.00383-2023.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.09.008"},{"key":"2024101710321938000_9.6.00383-2023.15","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.2003.011130"},{"key":"2024101710321938000_9.6.00383-2023.16","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","article-title":"Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial","volume":"9","author":"Harrison","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024101710321938000_9.6.00383-2023.17","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.04.00039004"},{"key":"2024101710321938000_9.6.00383-2023.18","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02446-2021"},{"key":"2024101710321938000_9.6.00383-2023.19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12931-022-01952-8","article-title":"ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving benralizumab in a real-life setting: the observational rEtrospective ANANKE study","volume":"23","author":"Menzella","year":"2022","journal-title":"Respir Res"},{"key":"2024101710321938000_9.6.00383-2023.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.08.2083"},{"key":"2024101710321938000_9.6.00383-2023.21","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12890-020-01220-9","article-title":"Real-life experience with benralizumab during 6 months","volume":"20","author":"Padilla-Galo","year":"2020","journal-title":"BMC Pulm Med"},{"key":"2024101710321938000_9.6.00383-2023.22","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3390\/jcm12030985","article-title":"Effectiveness of benralizumab in OCS-dependent severe asthma: the impact of 2 years of therapy in a real-life setting","volume":"12","author":"Vitale","year":"2023","journal-title":"J Clin Med"},{"key":"2024101710321938000_9.6.00383-2023.23","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.jaip.2023.03.009","article-title":"Severe asthma standard-of-care background medication reduction with benralizumab: ANDHI in practice substudy","volume":"11","author":"Louis","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024101710321938000_9.6.00383-2023.24","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1111\/all.14737","article-title":"Adherence to inhaled corticosteroids and clinical outcomes following a year of benralizumab therapy for severe eosinophilic asthma","volume":"76","author":"d'Ancona","year":"2021","journal-title":"Allergy"},{"key":"2024101710321938000_9.6.00383-2023.25","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/cea.13601","article-title":"Real-world experience with mepolizumab: does it deliver what it has promised?","volume":"50","author":"Schleich","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"2024101710321938000_9.6.00383-2023.26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaip.2021.09.023","article-title":"Anti-interleukin-5 therapy is associated with attenuated lung function decline in severe eosinophilic asthma patients from the Belgian Severe Asthma Registry","volume":"10","author":"Graff","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024101710321938000_9.6.00383-2023.27","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S2213-2600(21)00004-7","article-title":"The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study","volume":"9","author":"McDowell","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024101710321938000_9.6.00383-2023.28","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2009.124925"},{"key":"2024101710321938000_9.6.00383-2023.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808991"},{"key":"2024101710321938000_9.6.00383-2023.30","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.chest.2023.01.037","article-title":"Sputum type 2 markers could predict remission in severe asthma treated with anti-IL-5","volume":"163","author":"Moermans","year":"2023","journal-title":"Chest"},{"key":"2024101710321938000_9.6.00383-2023.31","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jaip.2018.08.021","article-title":"Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps","volume":"7","author":"Weinstein","year":"2019","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00383-2023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:30:52Z","timestamp":1740375052000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00383-2023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,11,27]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1183\/23120541.00383-2023"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00383-2023","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}